Clarient announced this week the commercial launch of its lung cancer test, Clarient Insight Dx Pulmotype, which it said aids physicians in guiding treatment for non-small cell lung cancer patients.

Clarient Insight Dx Pulmotype is a five-antibody immunohistochemistry test that can be used to aid in the histological distinction between adenocarcinoma and squamous cell carcinoma in NSCLC tumor specimens. NSCLC accounts for approximately 85 percent of the more than 200,000 lung cancer cases diagnosed each year, the company estimated.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.